Taiwan xinpinshengyi Group expects to enter the mainland medical market with the third generation of car-t immunocytotherapy developed by it

The third generation of car-t immunocytotherapy of Xinpin biomedical group was launched in the world on July 17, 2015 / BIOON / -- on July 16, 2015, Xinpin biomedical group, a high-tech enterprise of cancer prevention and medical care, held a medical science and technology release conference in Shangri La Hotel, Jing'an, Shanghai, on the technology and market prospect of immunocytotherapy for cancer The topic of immunotherapy for cancer has been widely concerned, and the safety and effectiveness of clinical experiments have been highly affirmed This time, xinpinshengyi group developed a more advanced third-generation car-t [UCAR] immunocytotherapy, which is expected to start clinical trials of blood cancer in 2016 Immunocytotherapy will be the first choice to treat cancer in the future and a new hope to cure cancer Mr Pan Junyou, chairman of xinpinshengyi group, has a significant clinical trial effect of car-t immunocytotherapy Car-t immunocytotherapy is to use the patient's own cells, extract the T cells in the blood, carry out biotechnology transformation, so that it can recognize the antigens on the surface of tumor cells, and then transfer these cells back to the patient to achieve the therapeutic effect of identifying and killing cancer cells Simply put, car-t technology is like a GPS navigation system for your T cells, which can identify cancer cells and kill them More and more evidences show that the effect of car-t treatment is very clear At the end of last year, the second phase clinical trial of car-t immunocytotherapy in the United States found amazing effect, relapsed All) after car-t treatment, 27 cancer cells in 30 people completely disappeared, from the original complete cure rate of less than 25%, after car-t treatment, the cure rate rose to more than 90% Twenty of these 27 people, after six months of follow-up, did not detect cancer cells, shocking the world In China, the first car-t cell immunotherapy in Peking University International Hospital was successfully completed this year An 8-year-old leukemia patient was in stable condition after cell immunotherapy At present, he has recovered and discharged for observation Dr Pang, immune cell expert of Xinpin biomedical group, explained the background of Xinpin biomedical group and the market prospect of the third generation car-t cell therapy Xinpin biomedical group is an integrated platform for cancer prevention, cell therapy research and health care Its technology has been authorized to domestic well-known biotechnology enterprises, widely used in major hospitals In the future, Xinpin biomedical group will be committed to the car-t cell research project Yuyue biomedical, a wholly-owned subsidiary of Xinpin biomedical group, will become the ninth biotechnology new drug company in the world and the first in Asia with car-t as its main business The third generation of cat-t [UCAR] immunocytotherapy developed by Xinpin biomedical not only improves its safety technically, but also increases the survival time of cells in vivo What's more gratifying is that it was estimated that the cost of doing car-t once was quite high, which may not be affordable for ordinary Chinese people at all However, through the improvement of the manufacturing process, Xinpin biomedical has reduced the manufacturing cost of car-t in the near future, the use of immunocytotherapy will not be so far away, so that most people can bear it and truly benefit mankind Car-t therapy has been proved to be able to cure cancer Due to the extremely high entry threshold and the inability to mass produce, even if there are 800 new drug companies developing car-t in the world, it is not enough Yuyue has unlimited potential in the future Xinpinshengyi Group expects to launch three new car-t therapies in the future, seizing more than $35 billion in "cancer eradication" business opportunities It is believed that with the continuous improvement of car-t technology, immunotherapy for cancer will be popularized in the future, and it is no longer a dream to cure cancer As a well-known biotechnology enterprise in Taiwan, Xinpin biomedical Group expects to enter the huge medical market in mainland China with the third generation of car-t immunocytotherapy developed by it A number of senior executives of xinpinshengyi group recently appeared in Shanghai to share the latest technology and market prospect of immunotherapy for cancer with their counterparts in mainland China Car-t immunocytotherapy is to use the patient's own cells, extract the T cells in the blood, carry out biotechnology transformation, so that it can recognize the antigens on the surface of tumor cells, and then transfer these cells back to the patient, so as to achieve the therapeutic effect of identifying and killing cancer cells "In a nutshell, car-t technology is like putting a GPS navigation system on your T cells to recognize cancer cells and kill them." Pan Junyou, chairman of xinpinshengyi group, said Although car-t therapy has been proved to have a good effect on cancer, but due to the extremely high threshold of entry and the inability to mass produce, there are only a few biotechnology enterprises focusing on the research and development of this technology in the world Pan Junyou said that Xinpin biomedical group is committed to the car-t cell research project, and Yuyue biology, a subsidiary of the group, will become the ninth biotechnology new drug company in the world and the first in Asia with car-t as its main business It is understood that the third generation car-t immunocytotherapy being developed by Xinpin biomedical group can not only improve the technical safety, prolong the survival time of immune cells in vivo, but also greatly reduce the manufacturing cost The Group expects to launch clinical trials of blood cancer in 2016 and launch three new car-t therapies For many years, cancer has been regarded as a "killer of human health" due to its low cure rate According to a study released by the International Center for cancer research, 21.35 million new cancer cases are expected to occur in the world by 2030 According to the estimate of the World Health Organization, the number of new cancer patients in China reached 3.07 million in 2012 According to pan Junyou, immunocytotherapy is expected to become the first choice for cancer treatment in the future, which also makes the demand for this biotechnology in the mainland medical market increasing day by day He revealed that the group is actively seeking cooperation with mainland medical institutions, hoping to bring the third generation of car-t immunotherapy to help more mainland cancer patients.